These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 11883079)
1. Designing and characterizing hammerhead ribozymes for use in AAV vector-mediated retinal gene therapies. Fritz JJ; White DA; Lewin AS; Hauswirth WW Methods Enzymol; 2002; 346():358-77. PubMed ID: 11883079 [No Abstract] [Full Text] [Related]
3. Design and validation of therapeutic hammerhead ribozymes for autosomal dominant diseases. Fritz JJ; Gorbatyuk M; Lewin AS; Hauswirth WW Methods Mol Biol; 2004; 252():221-36. PubMed ID: 15017052 [TBL] [Abstract][Full Text] [Related]
4. Development of hammerhead ribozymes to modulate endogenous gene expression for functional studies. Fritz JJ; Lewin A; Hauswirth W; Agarwal A; Grant M; Shaw L Methods; 2002 Oct; 28(2):276-85. PubMed ID: 12413427 [TBL] [Abstract][Full Text] [Related]
6. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells. Hayashidani Y; Hiyama E; Murakami Y; Sueda T Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of hepatitis B virus by lentiviral vector delivered antisense RNA and hammerhead ribozymes. Nash KL; Alexander GJ; Lever AM J Viral Hepat; 2005 Jul; 12(4):346-56. PubMed ID: 15985004 [TBL] [Abstract][Full Text] [Related]
9. Ribozyme knockdown of the gamma-subunit of rod cGMP phosphodiesterase alters the ERG and retinal morphology in wild-type mice. Liu J; Timmers AM; Lewin AS; Hauswirth WW Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3836-44. PubMed ID: 16186371 [TBL] [Abstract][Full Text] [Related]
10. Ribozymes: from mechanistic studies to applications in vivo. Ohkawa J; Koguma T; Kohda T; Taira K J Biochem; 1995 Aug; 118(2):251-8. PubMed ID: 8543555 [TBL] [Abstract][Full Text] [Related]
11. Design and production of asymmetric hammerhead ribozymes. Tabler M; Sczakiel G Methods Mol Biol; 1997; 74():141-9. PubMed ID: 9204429 [No Abstract] [Full Text] [Related]
12. Ribozymes in treatment of inherited retinal disease. Shaw LC; Whalen PO; Drenser KA; Yan W; Hauswirth WW; Lewin AS Methods Enzymol; 2000; 316():761-76. PubMed ID: 10800713 [No Abstract] [Full Text] [Related]
14. Ribozymes: structure, characteristics and use as potential antiviral agents. Bartolomé J; Madejón A; Carreño V J Hepatol; 1995; 22(1 Suppl):57-64. PubMed ID: 7602079 [TBL] [Abstract][Full Text] [Related]
15. Ribozymes as therapies for AIDS. Rossi JJ; Cantin EM; Zaia JA; Ladne PA; Chen J; Stephens DA; Sarver N; Chang PS Ann N Y Acad Sci; 1990; 616():184-200. PubMed ID: 2078019 [No Abstract] [Full Text] [Related]
16. PCR-based construction of long hammerhead ribozymes. Zillmann M; Robinson G Methods Mol Biol; 1997; 74():131-9. PubMed ID: 9204428 [No Abstract] [Full Text] [Related]
17. Engineered ribozymes as molecular tools for site-specific alteration of RNA sequence. Müller S Chembiochem; 2003 Oct; 4(10):991-7. PubMed ID: 14523916 [No Abstract] [Full Text] [Related]
19. Ribozymes: killing the messenger. Barinaga M Science; 1993 Dec; 262(5139):1512-4. PubMed ID: 8248799 [No Abstract] [Full Text] [Related]
20. In vivo RNA transcript-releasing plasmid possessing a universal pseudo-terminator by means of artificial ribozymes. Ohme-Takagi M; Shinshi H; Oda M; Uchimaru T; Nishikawa S; Taira K Nucleic Acids Symp Ser; 1990; (22):49-50. PubMed ID: 1714571 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]